Paul McBarron - 21 Dec 2023 Form 4 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)

Role
E. VP, Fin, CFO, COO and Secretary, Director
Signature
/s/ Paul McBarron
Issuer symbol
CYCC
Transactions as of
21 Dec 2023
Net transactions value
+$6,252
Form type
4
Filing time
26 Dec 2023, 16:05:25 UTC
Previous filing
03 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYCC Common Stock Purchase $6,252 +1,886 +6% $3.32 33,378 21 Dec 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYCC Warrants (right to buy) Purchase $0 +1,886 $0.000000 1,886 21 Dec 2023 Common Stock 1,886 $3.19 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person purchased unregistered shares of the Issuer's common stock in a private placement, pursuant to a Securities Purchase Agreement between the Reporting Person and the Issuer.
F2 Each share of common stock was purchased with an accompanying warrant at an aggregate purchase price of $3.315 per share and accompanying warrant.

Remarks:

E. VP, Fin, CFO, COO and Secretary